Results obtained by Gilead and Arcus could rekindle interest in the anti-TIGIT modality, which has seen many setbacks in the ...

MFN-driven drug price reductions in the US are unlikely to have a big impact pharma R&D spending, experts agree.

Sanofi acquired commercialisation rights for the radiopharmaceutical AlphaMedix from Orana Med in September 2024.

Cognivia Signal will try to predict which patients are at risk of dropping out to give sponsors the opportunity to intervene.

Nanobiotix's JNJ-1900, which is in Phase III for HNSCC, exhibited an ORR of 69% in oesophageal cancer, potentially ...

Lilly is continuing with its goal of submitting for approval of orforglipron in obesity by the end of 2025, and in type 2 diabetes in 2026. Image credit: Tada Images / Shutterstock.com Eli Lilly’s ...

The VESALIUS-CV trial (NCT03872401) has proved its long-term efficacy in these patients after meeting both its primary ...

While overall survival (OS) is the king endpoint in oncology trials, it may be overshadowed by surrogates such as progression-free survival (PFS) and objective response rates (ORR) as outcomes improve ...

Enanta Pharmaceuticals reported that the Phase IIb trial failed to meet its primary endpoint. Image credit: viewimage / Shutterstock.com. Enanta Pharmaceuticals has seen its stock more than double, ...

Japanese pharmaceutical company Takeda has withdrawn itself from the cell therapy space amid its efforts to prioritise its portfolio. Image credit: Anusorn Nakdee via ShutterStock.com. Japanese pharma ...

According to apolitical healthcare policy thinktank KFF, payments will more than double from $888 in 2025 to $1,904 on average annually in 2026 for ACA enrolees who receive subsidies if the ACA ...

Real-world evidence is derived from the analysis of data collected from real-world settings. Credit: Shutterstock The evaluation of new treatment effectiveness and patient safety has traditionally ...